22nd Century Group (XXII) Reiterated at Buy by Dawson James, New FDA Commissioner Expected to Move Forward on Low-Nicotine Mandate & Drive the Company's Value
Tweet Send to a Friend
Dawson James analyst James McILree reiterated a Buy rating and $8.50 price target on 22nd Century Group (NASDAQ: XXII), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
